Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Nov 24:10:409-418.
doi: 10.2147/ITT.S240891. eCollection 2021.

The Role of IL-17 Cytokines in Psoriasis

Megan Mosca  1 , Julie Hong  1 , Edward Hadeler  1 , Marwa Hakimi  1 , Wilson Liao  1 , Tina Bhutani  1
Affiliations
Review

The Role of IL-17 Cytokines in Psoriasis

Megan Mosca et al. Immunotargets Ther. .

Abstract

Psoriasis is a chronic inflammatory skin condition associated with immune dysregulation. The immunologic cascade mediated by the interleukin (IL)-17 pathway plays a critically important role in the pathogenesis of psoriasis. The IL-17 effectors (IL-17A, IL-17C, IL-17E, and IL17F) act on keratinocytes, endothelial cells, and immune cells to stimulate epidermal hyperplasia and the pro-inflammatory feed-forward cycle seen within plaque psoriasis. The IL-17 pathway is also hypothesized to modulate the inflammatory responses linking comorbid systemic diseases with psoriasis. Furthermore, the robust clinical response seen with current and emerging therapies targeting IL-17 emphasizes the importance of the IL-17 cytokines in the pathogenesis of psoriasis.

Keywords: IL-17; biologics; immune pathway; pathogenesis; plaque psoriasis.

PubMed Disclaimer

Conflict of interest statement

Dr. Tina Bhutani has received research funding from Abbvie, Celgene, Galderma, Janssen, Pfizer, Regeneron, and Sun. She has served as an advisor for Abbvie, Boehringer-Ingelheim, Bristol Myers Squibb, Pfizer, Leo, Lilly, UCB, and Novartis. Dr. Wilson Liao has received research grant funding from Abbvie, Amgen, Janssen, Leo, Novartis, Pfizer, Regeneron, and TRex Bio. Megan Mosca, Julie Hong, Edward Hadeler, and Dr. Marwa Hakimi have nothing to disclose.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Rachakonda TD, Schupp CW, Armstrong AW. Psoriasis prevalence among adults in the United States. J Am Acad Dermatol. 2014;70(3):512–516. doi:10.1016/j.jaad.2013.11.013 - DOI - PubMed
    1. Armstrong AW, Read C. Pathophysiology, clinical presentation, and treatment of psoriasis: a Review. JAMA. 2020;323(19):1945–1960. doi:10.1001/jama.2020.4006 - DOI - PubMed
    1. Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med. 2009;361(17):496–509. doi:10.1056/NEJMra0804595 - DOI - PubMed
    1. Aggarwal S, Ghilardi N, Xie M-H, de Sauvage FJ, Gurney AL. Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17. J Biol Chem. 2003;278(3):1910–1914. doi:10.1074/jbc.M207577200 - DOI - PubMed
    1. Gotesman RD, Vender R. Bimekizumab for moderate-to-severe plaque psoriasis. Skin Therapy Lett. 2021;26(3):1–4. - PubMed